Transcenta Holding Limited (HKG:6628)
Hong Kong · Delayed Price · Currency is HKD 1.175
+0.200 (20.51%)
Sep 21, 2026, 11:45 AM HKT
Transcenta Holding Revenue
Transcenta Holding had revenue of 23.60M CNY in the half year ending June 30, 2026, with 417.02% growth. This brings the company's revenue in the last twelve months to 28.32M, up 201.03% year-over-year. In the year 2025, Transcenta Holding had annual revenue of 7.44M, down -33.98%.
Revenue (ttm)
28.32M CNY
Revenue Growth
+201.03%
P/S Ratio
12.72
Revenue / Employee
188.81K CNY
Employees
150
Market Cap
415.98M HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 7.44M | -3.83M | -33.98% |
| Dec 31, 2024 | 11.26M | -42.59M | -79.09% |
| Dec 31, 2023 | 53.85M | -48.04M | -47.15% |
| Dec 31, 2022 | 101.89M | 51.65M | 102.80% |
| Dec 31, 2021 | 50.24M | -30.74M | -37.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Uni-Bio Science Group | 549.77M |
| 3D Medicines | 412.66M |
| Cutia Therapeutics | 383.95M |
| JW (Cayman) Therapeutics Co. | 333.25M |
| Kintor Pharmaceutical | 90.90M |
| Wuhan YZY Biopharma | 72.52M |
| Shanghai Bio-heart Biological Technology | 44.39M |
| Brii Biosciences | 40.23M |
Transcenta Holding News
- 8 months ago - Transcenta Collaborates With EirGenix To License HiCB Platform - Nasdaq